Nagler J, Miskovitz P
Am J Gastroenterol. 1981 Dec;76(6):495-9.
Eleven patients with symptoms of chronic postprandial idiopathic upper gastrointestinal distress served as their own controls in a clinical trial of a new prokinetic agent, domperidone. After evaluations to eliminate the presence of anatomic lesions, each subject was given domperidone and placebo in random order for one month. Using a symptom-scoring questionnaire, no superiority of domperidone over placebo could be demonstrated in the group as a whole. Improvement in two out of three patients with diabetic gastroparesis, however, was noted. Side-effects possibly related to domperidone consisted of gas pains and skin rash in one patient each.
